Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Debate 28A Fertility-sparing Surgery in Early-stage Endometrial Cancer is Safe and Does not Compromise Oncological Outcome
- Debate 28B Fertility-sparing Treatment for Early-stage Endometrial Cancer is Safe and Does Not Compromise Oncological Outcome
- Debate 29A Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endometrial Cancers
- Debate 29B Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endometrial Cancers
- Debate 30A Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?
- Debate 30B Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?
- Debate 31A What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?
- Debate 31B What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?
- Debate 32A How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial Lining be Managed?
- Debate 32B How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial Lining be Managed?
- Debate 33A What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Treated with Multimodal Therapy?
- Debate 33B What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Treated with Multimodal Therapy?
- Debate 34A Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?
- Debate 34B Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?
- Debate 35A Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?
- Debate 35B Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?
- Debate 36A Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?
- Debate 36B Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?
- Debate 37A Is there a Role for Using Immunotherapy in Endometrial Cancer?
- Debate 37B Is there a Role for Using Immunotherapy in Endometrial Cancer?
- Debate 38A What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?
- Debate 38B What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?
- Debate 39A What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Status Post Hysterectomy for Presumed Uterine Leiomyomas?
- Debate 39B What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Status Post Hysterectomy for Presumed Uterine Leiomyomas?
- Debate 40A Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?
- Debate 40B Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?
- Debate 41A Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?
- Debate 41B Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Debate 36B - Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?
No
from Section IV - Endometrial Cancer
Published online by Cambridge University Press: 20 July 2023
Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Debate 28A Fertility-sparing Surgery in Early-stage Endometrial Cancer is Safe and Does not Compromise Oncological Outcome
- Debate 28B Fertility-sparing Treatment for Early-stage Endometrial Cancer is Safe and Does Not Compromise Oncological Outcome
- Debate 29A Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endometrial Cancers
- Debate 29B Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endometrial Cancers
- Debate 30A Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?
- Debate 30B Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?
- Debate 31A What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?
- Debate 31B What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?
- Debate 32A How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial Lining be Managed?
- Debate 32B How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial Lining be Managed?
- Debate 33A What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Treated with Multimodal Therapy?
- Debate 33B What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Treated with Multimodal Therapy?
- Debate 34A Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?
- Debate 34B Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?
- Debate 35A Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?
- Debate 35B Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?
- Debate 36A Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?
- Debate 36B Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?
- Debate 37A Is there a Role for Using Immunotherapy in Endometrial Cancer?
- Debate 37B Is there a Role for Using Immunotherapy in Endometrial Cancer?
- Debate 38A What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?
- Debate 38B What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?
- Debate 39A What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Status Post Hysterectomy for Presumed Uterine Leiomyomas?
- Debate 39B What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Status Post Hysterectomy for Presumed Uterine Leiomyomas?
- Debate 40A Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?
- Debate 40B Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?
- Debate 41A Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?
- Debate 41B Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Summary
For recurrent/advanced endometrial cancer (EC), carboplatin in combination with paclitaxel remains the current first-line standard of care globally. In the NRG Oncology/GOG209 phase III trial, the median progression-free survival (PFS) and overall survival (OS) was 13 months and 37 months respectively (NRG/GOG209) [1]. Whilst hormonal therapy (HT) may be the preferred front-line systemic therapy for selected patients with low-grade EC carcinomas without rapidly progressive disease [2], we argue that the efficacy in advanced/recurrent EC post chemotherapy (i.e., chemo-resistant) is limited and alternative options should now be considered in clinical practice.
- Type
- Chapter
- Information
- 50 Big Debates in Gynecologic Oncology , pp. 219 - 222Publisher: Cambridge University PressPrint publication year: 2023
References
Miller, DS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol 2020;38(33):3841–3850.CrossRefGoogle ScholarPubMed
Concin, N, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021;31(1):12–39.CrossRefGoogle ScholarPubMed
Ethier, JL, et al. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol 2017;147(1):158–166.CrossRefGoogle ScholarPubMed
Mileshkin, L, et al. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial–ANZGOG 0903. Gynecol Oncol 2019;154(1):29–37.CrossRefGoogle ScholarPubMed
Mirza, MR, et al. A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus) advanced/recurrent endometrial cancer (EC): NSGO- PALEO/ENGOT-EN3 trial. Ann Oncol 2020;31(Suppl. 4):S1160. https://doi.org/10.1016/annonc/annonc325CrossRefGoogle Scholar
Leon-Castillo, A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020;38:3388e3397. https://doi.org/10.1200/JCO.20.00549CrossRefGoogle ScholarPubMed
Oaknin, A, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repaire-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020;6v11:1766e1772. https://doi.org/10.1001/jamaoncol.2020.4515CrossRefGoogle Scholar
Fader, AN, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 2020;26(15):3928e3935.CrossRefGoogle ScholarPubMed
Omalley, D, et al. KEYNOTE 158. Ann Oncol 2019;30(Suppl. 5):v403ev404. https://doi.org/10.1093/annonc/mdz25Google Scholar
Oaknin, A, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): results from GARNET. Ann Oncol 2020;31(Suppl. 4):S1142–S1215. 10.1016/annonc/annonc325CrossRefGoogle Scholar
Makker, V, et al. Study 309–KEYNOTE-775 Investigators. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386(5):437–448.Google Scholar
Colombo, N, et al. Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). Ann Oncol 2021;32(Suppl. 5):S725–S772. https://doi.org/10.1016/annonc/annonc703CrossRefGoogle Scholar